| Code | CSB-RA006163MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of ipilimumab, targeting CTLA-4 (CD152), an inhibitory immune-checkpoint receptor expressed on activated T cells and constitutively enriched on regulatory T cells (Tregs). CTLA-4 is a key negative regulator of T-cell priming, competing with CD28 for binding to CD80/CD86 (B7-1/B7-2) on antigen-presenting cells and dampening costimulatory signaling; CTLA-4 can also reduce ligand availability through mechanisms such as transendocytosis, shaping the amplitude of T-cell responses.
Ipilimumab is an anti-CTLA-4 monoclonal antibody that blocks CTLA-4 interaction with CD80/CD86, thereby augmenting T-cell activation and proliferation in immune-oncology settings. This biosimilar provides the antibody reagent for controlled studies of CTLA-4 checkpoint biology, including CD80/CD86 competitive binding dynamics, T-cell activation thresholds in co-culture assays, APC–T cell costimulation, and pathway-level immunomodulation relevant to checkpoint blockade research—without introducing confounding effects from additional therapeutic modalities.
There are currently no reviews for this product.